M Reuss-Borst1, U Hartmann, C Scheede, J Weiß. 1. Klinik Am Kurpark, Rehazentren DRV-Baden-Württemberg, Kurhausstr. 9, 97688 Bad Kissingen, Germany. m.reuss-borst@rehaklinik-am-kurpark.de
Abstract
UNLABELLED: In this prospective study, we measured bone mineral density (BMD) in 1,041 cancer patients undergoing an oncological rehabilitation program in an inpatient rehabilitation clinic. There was an osteoporosis prevalence of approximately 16%, independent of sex, which is considerably higher than in the community-dwelling population. INTRODUCTION: There is evidence that cancer patients are at risk of an increased BMD-loss following the disease and its therapy. Nevertheless, there is only little data available about the prevalence of osteoporosis in German cancer patients. Therefore, we measured BMD in 1,041 oncological inpatients undergoing rehabilitation. METHODS: From February 2006 to September 2009, BMD was measured in oncological patients with dual-energy x-ray absorptiometry (DXA; femur and spine). Statistical analysis for prevalence of osteoporosis was done in descriptive manner calculating means, standard deviation, frequencies, and 95% confidence intervals. To compare the prevalence of osteoporosis in different subgroups, χ (2) tests were done with p < 0.05. To create a risk profile, odds ratios were calculated using uni- and multivariate logistic regression. RESULTS: In 1,041 patients with a mean age of 57.1 years (11.0 years), DXA-measures were performed. Of them, 22% were male and 78% were female. The osteoporosis prevalence was about 16% (13.8, 18.2), independent of sex (p = 0.9722) or cancer type (p = 0.7174). As risk factors influencing the development of osteoporosis, age, weight, menopausal state, and hormone replacement therapy were identified in women and weight only in men. CONCLUSIONS: Compared to the general population, the rate of osteoporosis is distinctly elevated in German cancer patients independent of sex or cancer type. Hence, a general recommendation for a DXA screening in these patients appears to be justified.
UNLABELLED: In this prospective study, we measured bone mineral density (BMD) in 1,041 cancerpatients undergoing an oncological rehabilitation program in an inpatient rehabilitation clinic. There was an osteoporosis prevalence of approximately 16%, independent of sex, which is considerably higher than in the community-dwelling population. INTRODUCTION: There is evidence that cancerpatients are at risk of an increased BMD-loss following the disease and its therapy. Nevertheless, there is only little data available about the prevalence of osteoporosis in German cancerpatients. Therefore, we measured BMD in 1,041 oncological inpatients undergoing rehabilitation. METHODS: From February 2006 to September 2009, BMD was measured in oncological patients with dual-energy x-ray absorptiometry (DXA; femur and spine). Statistical analysis for prevalence of osteoporosis was done in descriptive manner calculating means, standard deviation, frequencies, and 95% confidence intervals. To compare the prevalence of osteoporosis in different subgroups, χ (2) tests were done with p < 0.05. To create a risk profile, odds ratios were calculated using uni- and multivariate logistic regression. RESULTS: In 1,041 patients with a mean age of 57.1 years (11.0 years), DXA-measures were performed. Of them, 22% were male and 78% were female. The osteoporosis prevalence was about 16% (13.8, 18.2), independent of sex (p = 0.9722) or cancer type (p = 0.7174). As risk factors influencing the development of osteoporosis, age, weight, menopausal state, and hormone replacement therapy were identified in women and weight only in men. CONCLUSIONS: Compared to the general population, the rate of osteoporosis is distinctly elevated in German cancerpatients independent of sex or cancer type. Hence, a general recommendation for a DXA screening in these patients appears to be justified.
Authors: Stephen Kaptoge; Jose A da Silva; Kim Brixen; David M Reid; Heikki Kröger; Torben L Nielsen; Marianne Andersen; Claus Hagen; Roman Lorenc; Steven Boonen; Marie-Christine de Vernejoul; Jan J Stepan; Judith Adams; Jean-Marc Kaufman; Jonathan Reeve Journal: Bone Date: 2008-04-16 Impact factor: 4.398
Authors: Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright Journal: Endocrine Date: 2015-01-31 Impact factor: 3.633
Authors: S Casla; P Hojman; I Márquez-Rodas; S López-Tarruella; Y Jerez; R Barakat; M Martín Journal: Clin Transl Oncol Date: 2014-06-04 Impact factor: 3.405
Authors: Shuman Yang; Na Wang; Jianmeng Wang; Lisa M Lix; William D Leslie; Baoming Yuan Journal: Arch Osteoporos Date: 2022-08-12 Impact factor: 2.879
Authors: R Rizzoli; J-J Body; M-L Brandi; J Cannata-Andia; D Chappard; A El Maghraoui; C C Glüer; D Kendler; N Napoli; A Papaioannou; D D Pierroz; M Rahme; C H Van Poznak; T J de Villiers; G El Hajj Fuleihan Journal: Osteoporos Int Date: 2013-10-22 Impact factor: 4.507
Authors: Fernando U Kay; Vinh Ho; Edmund B Dosunmu; Avneesh Chhabra; Keenan Brown; Xinhui Duan; Orhan K Öz Journal: Clin Nucl Med Date: 2021-01 Impact factor: 7.794
Authors: Sahar Zaidi; Showket Hussain; Shalini Verma; Zubia Veqar; Asiya Khan; Sheeraz Un Nazir; Neha Singh; Jamal Ali Moiz; Pranay Tanwar; Anurag Srivastava; G K Rath; Ravi Mehrotra Journal: Front Oncol Date: 2018-01-11 Impact factor: 6.244